经内镜逆行胰胆管造影术后胰腺炎防治的研究进展

张维锋; 李家速; 刘枫; 程益锋; 沈鹏

doi:10.3969/j.issn.1001-5256.2018.03.049

经内镜逆行胰胆管造影术后胰腺炎防治的研究进展

DOI: 10.3969/j.issn.1001-5256.2018.03.049

1. 海宁市人民医院急诊科
2. 第二军医大学附属长海医院消化内科

详细信息

中图分类号: R576
计量
- 文章访问数: 2711
- HTML全文浏览量: 37
- PDF下载量: 414
- 被引次数: 0
出版历程
- 出版日期: 2018-03-20

Research advances in the prevention and treatment of pancreatitis after endoscopic retrograde cholangiopancreatography

Emergency Department, Haining People's Hospital

摘要

摘要: 经内镜逆行胰胆管造影术(ERCP)是目前诊治胆胰疾病的一项重要技术,术后胰腺炎(PEP)是其最常见的并发症。自ERCP诞生以来,PEP防治便成为国际性研究焦点,近年来研究成果层出不穷,在危险因素、药物预防、预防性胰管支架置入等方面取得诸多进展。但研究结论不甚一致,仍需要临床进一步研究证实。
- 胰腺炎 /
- 胰胆管造影术,内窥镜逆行 /
- 综述
Abstract: Endoscopic retrograde cholangiopancreatography ( ERCP) is an important technique for the diagnosis and treatment of biliary and pancreatic diseases and post-ERCP pancreatitis ( PEP) is the most common complication of ERCP. Since the birth of ERCP, the prevention and treatment of PEP has become the focus of international research. In recent years, much progress has been made in the aspects of risk factors, pharmacological prevention, and prophylactic stent implantation in the pancreatic duct. Since these research findings are not consistent, further clinical studies are needed to demonstrate such findings.
- pancreatitis /
- cholangiopancreatography, endoscopic retrograde /
- review

HTML全文

参考文献(40)

[1]THAKER AM, MOSKO JD, BERZIN TM.Post-endoscopic retrograde cholangiopancreatography pancreatitis[J].Gastroenterol Rep (Oxf) , 2015, 3 (1) :32-40.

[2]DING X, ZHANG F, WANG Y.Risk factors for post-ERCP pancreatitis:A systematic review and meta-analysis[J].Surgeon, 2015, 13 (4) :218-229.

[3]DUMONCEAU JM, ANDRIULLI A, ELMUNZER BJ, et al.Prophylaxis of post-ERCP pancreatitis:European Society of Gastrointestinal Endoscopy (ESGE) guideline-updated June2014[J].Endoscopy, 2014, 46 (9) :799-815.

[4]HASHIMOTO S, ITO K, KOSHIDA S, et al.Risk factors for post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis and stent dysfunction after preoperative biliary drainage in patients with malignant biliary stricture[J].Intern Med, 2016, 55 (18) :2529-2536.

[5]FUJISAWA T, KAGAWA K, HISATOMI K, et al.Obesity with abundant subcutaneous adipose tissue increases the risk of postERCP pancreatitis[J].J Gastroenterol, 2016, 51 (9) , 931-938.

[6]EL NAKEEB A, EL HANAFY E, SALAH T, et al.Post-endoscopic retrograde cholangiopancreatography pancreatitis:risk factors and predictors of severity[J].World J Gastrointest Endosc, 2016, 8 (19) :709-715.

[7]KOKSAL AR, BOGA S, ALKIM H, et al.Chemerin:a new biomarker to predict postendoscopic retrograde cholangiopancreatography pancreatitis[J].Eur J Gastroenterol Hepatol, 2016, 28 (6) :714-721.

[8]INAMDAR S, BERZIN TM, SEJPAL DV, et al.Pregnancy is a risk factor for pancreatitis after endoscopic retrograde cholangiopancreatography in a National Cohort Study[J].Clin Gastroenterol Hepatol, 2016, 14 (1) :107-114.

[9]LEERHOY B, NORDHOLM-CARSTENSEN A, NOVOVIC S, et al.Effect of body weight on fixed dose of diclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis[J].Scand J Gastroenterol, 2016, 51 (8) :1007-1012.

[10]FINKELMEIER F, TAL A, AJOUAOU M, et al.ERCP in elderly patients:increased risk of sedation adverse events but low frequency of post-ERCP pancreatitis[J].Gastrointest Endosc, 2015, 82 (6) :1051-1059.

[11]PHILLIP V, SCHWAB M, HAF D, et al.Identification of risk factors for post-endoscopic retrograde cholangiopancreatography pancreatitis in a high volume center[J].PLo S One, 2017, 12 (5) :e0177874.

[12]TROENDLE DM, ABRAHAM O, HUANG R, et al.Factors associated with post-ERCP pancreatitis and the effect of pancreatic duct stenting in a pediatric population[J].Gastrointest Endosc, 2015, 81 (6) :1408-1416.

[13]MATSUBARA H, URANO F, KINOSHITA Y, et al.Analysis of the risk factors for severity in post endoscopic retrograde cholangiopancreatography pancreatitis:The indication of prophylactic treatments[J].World J Gastrointest Endosc, 2017, 9 (4) :189-195.

[14]HAYASHI S, NISHIDA T, SHIMAKOSHI H, et al.Combination of two-hour post-endoscopic retrograde cholangiopancreatography amylase levels and cannulation times is useful for predicting postendoscopic retrograde cholangiopancreatography pancreatitis[J].World J Gastrointest Endosc, 2016, 8 (20) :777-784.

[15]TRYLISKYY Y, BRYCE GJ.Role of heart rate variability in predicting post-endoscopic retrograde cholangiopancreatography pancreatitis[J].Acta Gastroenterol Belg, 2016, 79 (3) :429-434.

[16]PAPACHRISTOS A, HOWARD T, THOMSON BN, et al.Predicting post-endoscopic retrograde cholangiopancreatography pancreatitis using the 4-h serum lipase level[J].ANZ J Surg, 2018, 88 (1-2) :82-86.

[17]ZHANG FB, ZHU B, LIU W, et al.The clinical effect of octreotide combined with indomethacin on pancreatitis and hyperamylasemia after ERCP[J].Chin J Med Offic, 2015, 43 (7) :752-753, 755. (in Chinese) 章福彬, 朱斌, 刘卫, 等.奥曲肽联合吲哚美辛栓剂预防ERCP术后胰腺炎和高淀粉酶血症的临床研究[J].临床军医杂志, 2015, 43 (7) :752-753, 755.

[18]WAN J, REN Y, ZHU Z, et al.How to select patients and timing for rectal indomethacin to prevent post-ERCP pancreatitis:a systematic review and meta-analysis[J].BMC Gastroenterol, 2017, 17 (1) :43.

[19]SHEN C, SHI Y, LIANG T, et al.Rectal NSAIDs in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in unselected patients:systematic review and meta-analysis[J].Dig Endosc, 2017, 29 (3) :281-290.

[20]MOHAMMAD ALIZADEH AH, ABBASINAZARI M, HATAMI B, et al.Comparison of rectal indomethacin, diclofenac, and naproxen for the prevention of post endoscopic retrograde cholangiopancreatography pancreatitis[J].Eur J Gastroenterol Hepatol, 2017, 29 (3) :349-354.

[21]YANG C, ZHAO Y, LI W, et al.Rectal nonsteroidal anti-inflammatory drugs administration is effective for the prevention of postERCP pancreatitis:an updated meta-analysis of randomized controlled trials[J].Pancreatology, 2017, 17 (5) :681-688.

[22]FUJITA Y, HASEGAWA S, KATO Y, et al.Intravenous injection of low-dose flurbiprofenaxetil for preventing post-ERCP pancreatitis in high-risk patients:an interim analysis of the trial[J].Endosc Int Open, 2016, 4 (10) :e1078-e1082.

[23]HU J, LI PL, ZHANG T, et al.Role of Somatostatin in preventing post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis:an update meta-analysis[J].Front Pharmacol, 2016, 7:489.

[24]YUHARA H, OGAWA M, KAWAGUCHI Y, et al.Pharmacologic prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis:protease inhibitors and NSAIDs in a meta-analysis[J].J Gastroenterol, 2014, 49 (3) :388-399.

[25]YU G, LI S, WAN R, et al.Nafamostatmesilate for prevention of post-ERCP pancreatitis:a meta-analysis of prospective, randomized, controlled trials[J].Pancreas, 2015, 44 (4) :561-569.

[26]KIM SJ, KANG DH, KIM HW, et al.A randomized comparative study of 24-and 6-hour infusion of nafamostatmesilate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis:a prospective randomized comparison trial[J].Pancreas, 2016, 45 (8) :1179-1183.

[27]WU D, WAN J, XIA L, et al.The efficiency of aggressive hydration with lactated ringer solution for the prevention of Post-ERCP pancreatitis:a systematic review and meta-analysis[J].J Clin Gastroenterol, 2017, 51 (8) :e68-e76.

[28]WANG C, LI Q, YE P, et al.Value of raw rhubarb solution in the precaution of post-endoscopic retrograde cholangiopancreatography pancreatitis in patients with high-risk factors:a predictive random compared research in one center[J].Dig Dis Sci, 2017, 62 (4) :1043-1050.

[29]HAUSER G, BLAZEVIC I, SALKIC N, et al.Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography:a prospective, randomized, controlled trial[J].Surg Endosc, 2017, 31 (2) :602-610.

[30]GOOSHE M, ABDOLGHAFFARI AH, NIKFAR S, et al.Antioxidant therapy in acute, chronic and post-endoscopic retrograde cholangiopancreatography pancreatitis:an updated systematic review and meta-analysis[J].World J Gastroenterol, 2015, 21 (30) :9189-9208.

[31]VADALA di PRAMPERO SF, FALESCHINI G, PANIC N, et al.Endoscopic and pharmacological treatment for prophylaxis against postendoscopic retrograde cholangiopancreatography pancreatitis:a meta-analysis and systematic review[J].Eur J Gastroenterol Hepatol, 2016, 28 (12) :1415-1424.

[32]de MOURA ET, de MOURA EG, BERNARDO W, et al.Guide wirea sistedcannulation versus conventional contrast to prevent pancreatitis.A systematic review and meta-analysis based on randomized control trials[J].Rev Gastroenterol Peru, 2016, 36 (4) :308-319.

[33]BUXBAUM J, LEONOR P, TUNG J, et al.Randomized trial of endoscopist-controlled vs.assistant-controlled wire-guided cannulation of the bile duct[J].Am J Gastroenterol, 2016, 111 (12) :1841-1847.

[34]SAKAI Y, TSUYUGUCHI T, SUGIYAMA H, et al.Prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis by pancreatic duct stenting using a loop-tipped guidewire[J].World J Clin Cases, 2016, 4 (8) :213-218.

[35]TSE F, YUAN Y, MOAYYEDI P, et al.Double-guidewire technique in difficult biliary cannulation for the prevention of post-ERCP pancreatitis:a systematic review and meta-analysis[J].Endoscopy, 2017, 49 (1) :15-26.

[36]LI P, LU Y, ZHANG Y, et al.Effective application of Precut technique in patients with difficult ERCP intubation[J].J Clin Exp Med, 2017, 16 (21) :2144-2147. (in Chinese) 李攀, 卢媛, 张彦, 等.Precut技术在ERCP插管困难患者中的有效应用[J].临床和实验医学杂志, 2017, 16 (21) :2144-2147.

[37]MARIANI A, di LEO M, GIARDULLO N, et al.Early precut sphincterotomy for difficult biliary access to reduce post-ERCP pancreatitis:a randomized trial[J].Endoscopy, 2016, 48 (6) :530-535.

[38]ANG TL, KWEK AB, SONG M, et al.Comparative study of strategies for preventing post-ERCP pancreatitis after early precut sphincterotomy for biliary access[J].J Dig Dis, 2016, 17 (10) :692-696.

[39]ZAGALSKY D, GUIDI MA, CURVALE C, et al.Early precut is as efficient as pancreatic stent in preventing post-ERCP pancreatitis in high-risk subjects-A randomized study[J].Rev Esp Enferm Dig, 2016, 108 (9) :258-562.

[40]FUJISAWA T, KAGAWA K, HISATOMI K, et al.Is endoscopic papillary balloon dilatation really a risk factor for post-ERCP pancreatitis?[J].World J Gastroenterol, 2016, 22 (26) :5909-5916.

施引文献

资源附件(0)

访问统计